Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MINNEAPOLIS, JULY 28, 2026 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) (CVRX), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, ANNOUNCED TODAY THAT THE MANAGEMENT TEAM WILL PRESENT AT CANACCORD GENUITY'S 46TH ANNUAL GROWTH CONFERENCE IN BOSTON ON TUESDAY, AUGUST 11, 2026. THE COMPANY'S PRESENTATION WILL BEGIN AT 1:00 P.M. (ET).

CVRX TO PRESENT AT CANACCORD GENUITY'S 46TH ANNUAL GROWTH CONFERENCE

MINNEAPOLIS, JULY 23, 2026 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) ("CVRX"), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, TODAY ANNOUNCED THAT IT PLANS TO RELEASE SECOND QUARTER 2026 FINANCIAL AND OPERATING RESULTS AFTER MARKET CLOSE ON THURSDAY, AUGUST 6, 2026. THE COMPANY WILL HOST A CONFERENCE CALL TO REVIEW ITS RESULTS AT 4:30 P.M. EASTERN TIME THE SAME DAY. A LIVE WEBCAST OF THE INVESTOR CONFERENCE CALL WILL BE AVAILABLE ONLINE AT THE INVESTOR RELATIONS PAGE OF THE COMPANY'S WEBSITE AT IR.CVRX.COM. TO LISTEN TO THE CONFERENCE CALL ON YOUR TELEPHONE, PLEASE DIAL 1- 877-704-4453 FOR U.S. CALLERS, OR 1-201-389-0920 FOR INTERNATIONAL CALLERS, APPROXIMATELY TEN MINUTES PRIOR TO THE START TIME. ABOUT CVRX, INC. CVRX IS A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES. BAROSTIM IS THE FIRST MEDICAL TECHNOLOGY APPROVED BY FDA THAT USES NEUROMODULATION TO IMPROVE THE SYMPTOMS OF PATIENTS WITH HEART FAILURE. BAROSTIM IS AN IMPLANTABLE DEVICE THAT DELIVERS ELECTRICAL PULSES TO BARORECEPTORS LOCATED IN THE WALL OF THE CAROTID ARTERY. THE THERAPY IS DESIGNED TO RESTORE BALANCE TO THE AUTONOMIC NERVOUS SYSTEM AND THEREBY REDUCE THE SYMPTOMS OF HEART FAILURE. BAROSTIM RECEIVED THE FDA BREAKTHROUGH DEVICE DESIGNATION AND IS FDA-APPROVED FOR USE IN HEART FAILURE PATIENTS IN THE U.S. IT HAS BEEN CERTIFIED AS COMPLIANT WITH THE EU MEDICAL DEVICE REGULATION (MDR) AND HOLDS CE MARK FOR HEART FAILURE AND RESISTANT HYPERTENSION IN THE EUROPEAN ECONOMIC AREA. TO LEARN MORE ABOUT BAROSTIM, VISIT WWW.CVRX.COM. INVESTOR CONTACT:MARK KLAUSNER OR MIKE VALLIEICR HEALTHCARE443-213-0501 IR@CVRX.COM MEDIA CONTACT:EMILY MEYERSCVRX, INC.763-416-2853 EMEYERS@CVRX.COM

CVRX TO REPORT SECOND QUARTER 2026 FINANCIAL AND OPERATING RESULTS AND HOST CONFERENCE CALL ON AUGUST 6, 2026

MINNEAPOLIS, JUNE 09, 2026 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) (CVRX), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, ANNOUNCED TODAY THAT JARED OASHEIM, THE COMPANY'S CHIEF FINANCIAL OFFICER, WILL BE STEPPING DOWN FROM HIS ROLE TO PURSUE OTHER PROFESSIONAL OPPORTUNITIES. TO SUPPORT A SEAMLESS TRANSITION, MR. OASHEIM WILL REMAIN WITH THE COMPANY UNTIL A SUCCESSOR IS APPOINTED AND REMAIN AVAILABLE AS AN ADVISOR THROUGH FEBRUARY 2027. JARED HAS BEEN AN INTEGRAL PART OF CVRX SINCE 2015, AND HAS MADE A LASTING MARK ON OUR COMPANY OVER THE PAST DECADE SAID KEVIN HYKES, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF CVRX. HE LED CVRX THROUGH ITS INITIAL PUBLIC OFFERING AND BUILT THE DISCIPLINED FINANCE ORGANIZATION THAT SUPPORTS OUR COMMERCIAL GROWTH TODAY, ALL WHILE STAYING FOCUSED ON OUR MISSION TO IMPROVE THE LIVES OF PATIENTS WITH HEART FAILURE. WE ARE GRATEFUL FOR HIS MANY CONTRIBUTIONS AND WISH HIM EVERY SUCCESS. IT HAS BEEN A PRIVILEGE TO HELP BUILD CVRX ALONGSIDE SUCH A DEDICATED TEAM AND TO PLAY A PART IN BRINGING BAROSTIM TO MORE PATIENTS, SAID JARED OASHEIM, CHIEF FINANCIAL OFFICER OF CVRX. TAKING THE COMPANY PUBLIC AND HELPING ESTABLISH ITS FINANCIAL FOUNDATION HAS BEEN ONE OF THE HIGHLIGHTS OF MY CAREER. I AM COMMITTED TO A SEAMLESS TRANSITION AND LOOK FORWARD TO SEEING CVRX CONTINUE ITS MOMENTUM. THE COMPANY IS INITIATING A SEARCH TO IDENTIFY ITS NEXT CHIEF FINANCIAL OFFICER. PRESENTATION AT GOLDMAN SACHS HEALTHCARE CONFERENCE AS PREVIOUSLY ANNOUNCED, KEVIN HYKES AND JARED OASHEIM WILL PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE IN MIAMI ON WEDNESDAY, JUNE 10, 2026 AT 8:00 A.M. (ET). A LIVE WEBCAST OF THE EVENT CAN BE FOUND AT IR.CVRX.COM. AN ARCHIVED VERSION OF THE PRESENTATION WILL BE AVAILABLE FOLLOWING THE LIVE EVENT AND CAN BE ACCESSED AT THE SAME LOCATION FOR A LIMITED TIME. ABOUT CVRX, INC. C

CVRX ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION

MINNEAPOLIS, MAY 27, 2026 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) (CVRX), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, ANNOUNCED TODAY THAT THE MANAGEMENT TEAM WILL PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE IN MIAMI ON WEDNESDAY, JUNE 10, 2026. THE COMPANY'S PRESENTATION WILL BEGIN AT 8:00 A.M. (ET).

CVRX TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

MINNEAPOLIS, MAY 20, 2026 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) (CVRX), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, ANNOUNCED TODAY THAT THE MANAGEMENT TEAM WILL PRESENT AT THE WILLIAM BLAIR 46TH ANNUAL GROWTH STOCK CONFERENCE IN CHICAGO ON TUESDAY, JUNE 2, 2026. THE COMPANY'S PRESENTATION WILL BEGIN AT 10:40 A.M. (CT).

CVRX TO PRESENT AT THE WILLIAM BLAIR 46TH ANNUAL GROWTH STOCK CONFERENCE

MINNEAPOLIS, MAY 14, 2026 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) (CVRX), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, ANNOUNCED TODAY THAT HUMANA HAS ISSUED A MEDICARE ADVANTAGE COVERAGE POLICY FOR BAROSTIM THERAPY, EFFECTIVE MAY 1, 2026. HUMANA, A NATIONAL HEALTH INSURANCE COMPANY WITH THE SECOND LARGEST MEDICARE ADVANTAGE PROGRAM IN THE U.S., PROVIDES COVERAGE TO APPROXIMATELY 5.2 MILLION MEDICARE ADVANTAGE MEMBERS ACROSS 46 STATES.

CVRX ANNOUNCES HUMANA MEDICARE ADVANTAGE COVERAGE POLICY FOR BAROSTIM THERAPY

MINNEAPOLIS, MAY 11, 2026 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) ("CVRX"), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, TODAY ANNOUNCED ITS FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER OF 2026. RECENT HIGHLIGHTS TOTAL REVENUE FOR THE FIRST QUARTER OF 2026 WAS $14.8 MILLION, AN INCREASE OF APPROXIMATELY 20% OVER THE PRIOR YEAR QUARTER U.S. REVENUE FOR THE FIRST QUARTER OF 2026 WAS $13.7 MILLION, AN INCREASE OF 22% OVER THE PRIOR YEAR QUARTER ACTIVE IMPLANTING CENTERS IN THE U.S. GREW TO 257 AS OF MARCH 31, 2026, AS COMPARED TO 227 AS OF MARCH 31, 2025 FIRST SITE ACTIVATED AND FIRST PATIENT ENROLLED IN BENEFIT-HF CLINICAL TRIAL "WE DELIVERED A STRONG START TO 2026, WITH U.S. REVENUE GROWING 22% AS THE INVESTMENTS WE MADE IN OUR TEAM AND PROGRAMS THROUGHOUT 2025 BEGIN TO TRANSLATE INTO RESULTS," SAID KEVIN HYKES, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF CVRX.

CVRX REPORTS FIRST QUARTER 2026 FINANCIAL AND OPERATING RESULTS

MINNEAPOLIS, MAY 04, 2026 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX), A MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, TODAY ANNOUNCED THE ENROLLMENT OF THE FIRST PATIENT IN THE LANDMARK BENEFIT-HF TRIAL AT NORTH CENTRAL HEART - A DIVISION OF THE AVERA HEART HOSPITAL, IN SIOUX FALLS, S.D. BY DR. ORVAR JONSSON.

CVRX ANNOUNCES FIRST PATIENT ENROLLMENT IN BENEFIT-HF, A LANDMARK HEART FAILURE TRIAL EVALUATING BAROSTIM IN SIGNIFICANTLY EXPANDED POPULATION

MINNEAPOLIS, APRIL 27, 2026 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) ("CVRX"), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, TODAY ANNOUNCED THAT IT PLANS TO RELEASE FIRST QUARTER 2026 FINANCIAL AND OPERATING RESULTS AFTER MARKET CLOSE ON MONDAY, MAY 11, 2026. THE COMPANY WILL HOST A CONFERENCE CALL TO REVIEW ITS RESULTS AT 4:30 P.M. EASTERN TIME THE SAME DAY.

CVRX TO REPORT FIRST QUARTER 2026 FINANCIAL AND OPERATING RESULTS AND HOST CONFERENCE CALL ON MAY 11, 2026

MINNEAPOLIS, APRIL 20, 2026 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX), A MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, ANNOUNCED TODAY THE NOMINATION OF MICHAEL DALE TO SERVE ON ITS BOARD OF DIRECTORS. MR. DALE WILL STAND FOR ELECTION AT THE ANNUAL MEETING OF STOCKHOLDERS SCHEDULED FOR JUNE 1, 2026.

CVRx, Inc.

CVRX

Price

Financial Reports

No items found.

Press Releases

CVRx, Inc.

CVRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CVRX